Strides Pharma Science
- Market cap
- ₹ 9,270 Cr.
- P/E
- 16.1x
- P/B
- 2.96x
- 52-week range
- 768.65 – 1,260.9
- ROE
- 20%
- ROCE
- 18%
- Dividend yield
- 0.5%
- Debt / equity
- 0.57
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Strides Pharma Science against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)16.1 against a typical 34: cheaper than most peers (1st = cheapest).40th of 220
- Sales growth+12.9% against a typical +15.6% from a year earlier.107th of 197
- Profit growth+55.7% against a typical +18.9% from a year earlier.48th of 160
- Share price, 3 months+1.9% against a typical −0.5%.88th of 200
- Size₹ 9,269.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).41st of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A+ / CARE A1 | Stable | 12 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 12 Oct 2026 | Reaffirmed | CARE A+ → CARE A+ / CARE A1 | — | CARE | ₹ 2,200 Cr. | |
| 8 Jul 2026 | ▲ Upgrade | CARE A+ | — | CARE | ₹ 2,200 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 31 Jul 2026 | Financial Results | To consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter ended Jun 30, 2026 |
| 18 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 31 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 29 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 22 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Expenses | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 |
| Operating Profit | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 |
| OPM % | 11% | 13% | 16% | 18% | 16% | 18% | 18% | 19% | 19% | 20% | 18% | 18% |
| Other Income | −129 | 60 | −27 | 3,299 | 25 | 4 | −12 | 0 | 18 | 104 | 3 | 68 |
| Interest | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| Profit before tax | −157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 |
| Tax % | −5% | 23% | 55% | 1% | 16% | 21% | 20% | 13% | 14% | 15% | 13% | 17% |
| Net Profit | −149 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS in Rs | −14.54 | 5.4 | 1.98 | 364.69 | 7.81 | 9.54 | 8.91 | 10.8 | 13.84 | 21.93 | 13.77 | 17.02 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 8%
- 3 Years
- 10%
- TTM
- 8%
- 10 Years
- 16%
- 5 Years
- 20%
- 3 Years
- 71%
- TTM
- 55%
- 10 Years
- 8%
- 5 Years
- 28%
- 3 Years
- 72%
- TTM
- —
- 10 Years
- 22%
- 5 Years
- 31%
- 3 Years
- 57%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Strides Pharma Science | ₹ 1,080.10 | ₹ 9,270 Cr. | 16.1x | 3x | 20% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Badree Komandur
- Group Chief Executive Officer, Managing Director, Executive Director
- Vikesh Kumar
- Group Chief Financial Officer
- Manjula Ramamurthy
- Compliance Officer, Company Secretary
- Venkata Seetharama Raju Pakalapati
- Executive Director
- Umesh Kale
- Chief of Quality Services
Prices are delayed and for information only. Nothing on this page is investment advice.